Title
Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients.

Permalink
https://escholarship.org/uc/item/55g370t5

Authors
Owens, Geoffrey C
Garcia, Alejandro J
Mochizuki, Aaron Y
et al.

Publication Date
2019-01-29

DOI
10.3389/fimmu.2019.00121

Peer reviewed
Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients

Geoffrey C. Owens 1*, Alejandro J. Garcia 2, Aaron Y. Mochizuki 2,3, Julia W. Chang 1,4, Samuel D. Reyes 1, Noriko Salamon 5, Robert M. Prins 1,4,7,8, Gary W. Mathern 1,4,7,9 and Aria Fallah 1,7,9

1 Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 2 Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 3 Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 4 Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 5 Department of Radiological Sciences, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, United States, 6 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 7 Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 8 Parker Institute for Cancer Immunotherapy, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 9 Mattel Children’s Hospital, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Brain-infiltrating lymphocytes (BILs) were isolated from resected brain tissue from 10 pediatric epilepsy patients who had undergone surgery for Hemimegalencephaly (HME) (n = 1), Tuberous sclerosis complex (TSC) (n = 2), Focal cortical dysplasia (FCD) (n = 4), and Rasmussen encephalitis (RE) (n = 3). Peripheral blood mononuclear cells (PBMCs) were also isolated from blood collected at the time of the surgery. Cells were immunostained with a panel of 20 antibody markers, and analyzed by mass cytometry. To identify and quantify the immune cell types in the samples, an unbiased clustering method was applied to the entire data set. More than 85 percent of the CD45 + cells isolated from resected RE brain tissue comprised T cells; by contrast NK cells and myeloid cells constituted 80–95 percent of the CD45 + cells isolated from the TSC and the FCD brain specimens. Three populations of myeloid cells made up >50 percent of all of the myeloid cells in all of the samples of which a population of HLA-DR + CD11b + CD4 − cells comprised the vast majority of myeloid cells in the BIL fractions from the FCD and TSC cases. CD45RA + HLA-DR− CD11b + CD16 + NK cells constituted the major population of NK cells in the blood from all of the cases. This subset also comprised the majority of NK cells in BILs from the resected RE and HME brain tissue, whereas NK cells defined as CD45RA− HLA-DR + CD11b− CD16− cells comprised 86–96 percent of the NK cells isolated from the FCD and TSC brain tissue. Thirteen different subsets of CD4 and CD8 αβ T cells and γδ T cells accounted for over 80% of the CD3 + T cells in all of the BIL and PBMC samples. At least 90 percent of the T cells in the RE BILs, 80 percent of the T cells in the HME BILs and 40–66 percent in the TSC and FCD BILs comprised...
activated antigen-experienced (CD45RO+ HLA-DR+ CD69+) T cells. We conclude that even in cases where there is no evidence for an infection or an immune disorder, activated peripheral immune cells may be present in epileptogenic areas of the brain, possibly in response to seizure-driven brain inflammation.

**INTRODUCTION**

It has been estimated that by 15 years of age, approximately one percent of children will have experienced at least one seizure (1). For reasons that may not always be understood ∼10% of children go on to develop medically refractory epilepsy, which is defined as a failure of two or more antiepileptic drugs to control seizures, and at least one seizure per month for ≥18 months (2). Recurrent seizures may severely impair a child’s cognitive development leading to lifelong learning and behavioral difficulties. For children with drug-resistant epilepsy, surgery may be the only option to obtain seizure freedom, but will result in neurological deficits if the zone of resection involves eloquent cerebral cortex.

Many of the children who are candidates for epilepsy surgery suffer from rare neurological disorders including Rasmussen encephalitis (RE), Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia (FCD), and Hemimegalencephaly (HME). RE patients present with partial (focal) seizures; genetic or somatic mutations in the MTOR gene, and in genes that regulate mTOR activity (3). Histopathological examination of resected brain tissue and brain biopsies show T cells in perivascular spaces, leptomeninges, and in small clusters scattered throughout the affected gray and white matter (5, 6). Clonally focused T cells have been found in resected RE brain tissue strongly implicating an antigen driven immune response in disease etiology (7–10).

In TSC patients, germ line and somatic dominant loss of function mutations in the genes encoding hamartin (TSC1) or tuberin (TSC2) can cause the development of benign tumors and, abnormally differentiated cortical neuronal progenitors that may cause focal seizures (11). Tuberin and hamartin are components of a complex that regulates the activity of the protein kinase, mTOR (12). Similarly, FCD and HME can be caused by activating somatic mutations in the MTOR gene, and in genes that regulate mTOR activity (13–15). Histopathological examination of resected brain tissue and analysis of RNA transcripts has shown that FCD and TSC lesions may be associated with an inflammatory reaction (11, 16–19).

In the present study we report on the characterization, by mass cytometry, of brain-infiltrating lymphocytes (BILs) isolated from surgical resections of epileptogenic tissue to treat FCD, TSC, and HME, as well as RE, and of peripheral blood mononuclear cells (PBMCs) prepared from blood collected at the time of surgery from the same cases. Immune cell profiling showed that activated T cells were present in brain tissue from all of the cases examined, and that the relative abundance of adaptive and innate lymphoid cells, and myeloid cells markedly differed between the RE and non-RE cases.

**METHODS**

**Patient Cohort**

Under UCLA IRB approval (IRB#18-000154) brain tissue and blood were collected at surgery as part of UCLA’s Pediatric Epilepsy Surgery Program. All of the patients or their parents or legal guardians provided informed consent for the use of the surgical remnant and blood for research purposes. All specimens were collected using the same standard operating procedures. De-identified patient information including age at seizure onset, age at surgery, gender, and affected cerebral hemisphere was collected with informed consent (Table S1).

**Isolation of Peripheral Blood Lymphocytes and Brain-Infiltrating Lymphocytes**

PBMCs were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ). BILs were isolated from collagenase-treated brain tissue by fractionation on a step gradient (20). Briefly, brain tissue was diced manually on ice in dissociation solution (HBSS with 20 mM HEPES pH 7.0, 5 mM glucose, and 50 U/ml penicillin/streptomycin). Tissue fragments were incubated with agitation at room temperature overnight in dissociation solution containing 0.5 mg/ml Type IV collagenase (Warthong Biochemical Corp., Lakewood, NJ) and 5% filtered human serum (Mediatech Inc., Manassas, VA). The dissociated tissue was fractionated on a 30%: 70% Percoll® (SigmaAldrich, St. Louis, MO) step gradient in RPMI containing 20 mM HEPES. PBMCs and BILs were cryopreserved in 90% human serum /10% DMSO.

**Multiparameter Mass Cytometry**

The panel comprised the following markers: CD45 (89Y or 154Sm), CD196 (141Pr), CD19 (142Nd), CD69 (144Nd), CD4 (145Nd), CD8 (146Nd), CD25 (149Sm), CD103 (151Eu), CD45RA (155Gd), CD183 (156Gd), CD56 (163Dy), CD16 (164Dy), CD16 (165Ho), TCRγδ (168Er), CD3 (170Er), CD195 (171Yb), HLA-DR (174Yb), CD194 (175Yb), CD127 (176Yb), and CD11b (209Bi). All metal-tagged antibodies (Abs) were obtained from Fluidigm (San Francisco, CA) except the CD8 and TCRγδ antibodies, which were conjugated in-house. PBMCs and BILs were stained according to Fluidigm’s protocol. In brief, cells were thawed, and washed in phosphate-buffered saline (PBS); prior to staining BILs were filtered through a 40 µm sieve to remove any aggregates. Cells were resuspended in 1 ml of PBS and stained for 5 min with 1 µM Cisplatin. After quenching the staining with Maxpar® cell staining buffer (Fluidigm), cells were incubated with agitation at room temperature overnight in dissociation solution containing 0.5 mg/ml Type IV collagenase (Warthong Biochemical Corp., Lakewood, NJ) and 5% filtered human serum (Mediatech Inc., Manassas, VA).
were incubated with the cocktail of Abs in 100 μl of Maxpar® cell staining buffer for 30 min at room temperature. The Ab cocktail for staining PBMCs contained the CD45 Ab conjugated to Samarium 154 (154Sm) while the BIL Ab cocktail contained the CD45 Ab tagged with Yttrium 89 (89Y). Following two wash steps, cells were fixed overnight at 4°C in Maxpar® fixation and permeabilization buffer containing 0.125 μM Intercalator-Ir (Fluidigm). BILs and PBMCs from the same surgery were combined at this point and washed twice with Maxpar® cell staining buffer and a further two times with water. Having barcoded the BILs and PBMCs with a different metal-conjugated CD45 Ab it was possible to analyze them as single sample, thus the larger number of PBMCs served as a carrier for the smaller number of BILs that were isolated from brain tissue. Cells were resuspended in 10 percent EQ™ Four Element Calibration Beads (Fluidigm) containing Cerium (140/142Ce), Europium (151/153Eu), Holmium (165Ho), and Lutetium (175/176Lu). Samples were acquired on a Helios™ cytometry time of flight (CyTOF) system (Fluidigm) at an event rate of 300–500 events/s. Post-acquisition data normalization was done using bead-based normalization in the CyTOF software. Prior to analysis, data were gated to eliminate normalization beads, debris, dead cells, and doublets.

The analysis of FCS files was initially carried out using Cytobank (21). For each surgery case, the marker expression on the BILs was resolved by first gating live singlets on CD45 (89Y). Conversely marker expression on PBMCs was resolved by first gating on CD45 (154Sm). The data were then split into two separate FCS files using software tools in Cytobank (21). To define subsets of immune cells in each BIL and PBMC population, the entire high dimensional dataset (comprising 20 FCS files) was converted into a matrix of pair-wise similarities by implementing the t-based stochastic neighbor embedding (t-SNE) algorithm, followed by a density-based clustering method (ClusterX) (22). The resulting 2-D plots from this procedure were exported to CorelDraw2017 as portable document format files (Corel Corporation, Ottawa, Canada). Individual FCS files were analyzed using Flowjo® software (Flowjo LLC, Ashland, OR); 2-D contour plots were exported as scalable vector graphic (svg) files to CorelDraw2017. The median level of expression of each marker was used to assign a phenotypic identity to each cluster. Heat maps were generated using Morpheus software (www.broadinstitute.org) and exported to CorelDraw2017 as svg files. Principal component analysis (PCA) was performed using PAST software (https://palaeo-electronica.org/2001_1/past/issue1_01.htm).

RESULTS

PBMCs and BILs isolated from 10 pediatric epilepsy cases were analyzed by CyTOF using a panel of antibodies designed to identify populations of adaptive lymphoid cells, innate lymphoid cells, and myeloid cells. Implementing the mass cytometry data analysis pipeline developed by Chen et al. (21) generated 46 clusters, corresponding to putatively distinct populations of CD45+ cells (Figure 1). Clusters were classified as T cells, NK cells, and myeloid cells based on the relative expression of 19 immune cell markers. Immune cell clusters were divided into a CD3+ (n = 30, median CD3 expression values of 4.648–6.283) and a CD3− group (n = 16, median expression values of 0.001–0.81). The CD3+ group was subdivided into subsets of CD4, CD8, and γδ T cells based on the level of expression of these three phenotypic markers (Figure 2). The CD3− group was further divided into five NK cell subsets, ten myeloid and one B cell population based on the expression of CD56 and CD19 (Figure 2; Table S2).

Visual inspection of the t-SNE plots (Figure 1) showed that there were clear differences between the BILs from each surgical case compared with the corresponding PBMCs. On the other hand, the profiles of BILs from the two TSC (Case IDs 460 and 462) and the four FCD cases (Case IDs 475, 490, 494, and 495) appeared to be very similar and distinct from the three RE cases (Case IDs 472, 484, and 497), and dissimilar from the HME (Case ID 485), which appeared more similar to the RE cases. Principal components analysis based on the relative abundance of all of the clusters in each sample (percentages of CD45+ cells) confirmed this observation, and also showed that the immune cell profiles of PBMCs from all of the cases were very similar (Figure 3). From the magnitude of the PCA loading values (Table S3), Clusters 1 and 8 accounted for the largest amount of variance in the first component, thus, the relative numbers of NK and myeloid cells in the BIL fractions appears to explain in large measure the observed difference between the TSC and FCD BILS compared with the RE and HME BILs. As summarized in Figure 4, CD45+ cells from the FCD and TSC brain tissue specimens comprised far more NK cells and myeloid cells than CD45+ RE BILs, which in agreement with previous studies (5, 6, 20, 23), were predominantly CD8+ αβ T and γδ cells, The HME BILs comprised approximately equal numbers of T cells, NK cells and myeloid cells.

Three populations of myeloid cells (Clusters 1, 7, and 45) (Figure 2) made up >50 percent of all of the myeloid cells in all of the samples (Figure 5; Table S4). The Cluster 1 myeloid population comprised the vast majority of CD11b+ cells in the BIL fractions from the FCD and TSC cases (Figure 5), whereas Cluster 7 CD11b+ myeloid cells were more abundant in two of the three RE BIL fractions (Case IDs 472 and 484), and in all of the PBMCs (Figure 5). The only other marker that defined the Cluster 1 population was HLA-DR, thus it was not possible to assign a definitive phenotype to cells in this population, but they are likely to be macrophages. Likewise, Cluster 7 cells, which are CD3− CD4+ could constitute a dendritic cell or monocyte population, but additional markers are also required to adequately define this population.

Cluster 3 NK cells are CD56+ CD45RA+ HLA-DR− CD11b+ CD16+ (Figure 2), and constituted the major population of NK cells in the blood from all of the cases (Figure 5). This subset also comprised the majority of NK cells that were found in BILs from the resected RE and HME brain tissue (Figure 5). By contrast, Cluster 8 NK cells, defined as CD56+ CD45RA− HLA-DR+ CD11b− CD16− (Figure 2) comprised 86–96 percent of the NK cells isolated from the FCD and TSC brain tissue (Figure 5; Table S4). We confirmed the existence of Cluster 3.
FIGURE 1 | t-SNE plots showing the relative number of different immune cells in BILs and PBMCs from the pediatric epilepsy surgeries. The expression of 20 immune cell markers was analyzed by CyTOF. To define subsets of CD45+ cells in each BIL and PBMC population, the entire high dimensional dataset (comprising 20 FCS files) was converted into a matrix of pair-wise similarities by implementing the t-based stochastic neighbor embedding (t-SNE) algorithm, followed by a density-based clustering method (ClusterX). The clusters were assigned as either T cells, NK cells, myeloid cells, or B cells based on the median expression values of specific immune cell markers (CD3, CD4, CD8, TCR γδ, CD11b, CD56, and CD19).
Assignment of immune cell phenotypes. The median expression values of 19 immune cell markers, calculated by the Cytofit software, were used to assign a phenotype to each cluster of CD45+ cells (Table S2). The data were first separated into CD3+ and CD3− clusters, and the CD3+ populations were further subdivided into CD4+, CD8+, γδ subsets. The CD3− populations were categorized as myeloid, natural killer cell, or B cell based on the expression of CD56 and CD19. Heat maps generated from the median expression values included all the markers that were expressed on cells in the CD3+CD4+, CD3+CD8+, CD3+γδ, CD3−CD56+, CD3−CD19+− clusters, respectively. The median expression value of the two different CD45 antibody metal conjugates used to stain the PBMC and BIL fractions reflects the relative number of PBMCs and BILs in each cluster.

and 8 NK cell populations by manually curating the original FCS files from FCD case 490 using the FlowJo software package (Figure S1A).

Six subpopulations of CD4+ αβ T cells (Clusters 2, 5, 9, 12, 15, and 23), four of CD8+ αβ T cells (Clusters 4, 10, 13, and 14), and three subsets of γδ T cells (Clusters 11, 26, and 42) accounted for over 80% of the CD3+ T cells in all of the BIL and PBMC samples, although there were marked differences in the proportion of the different T cell subsets between the BIL and PBMC samples (Figure 5; Table S4). Clusters 2, 9 and 23 CD4+ T cells constitute naïve T cell populations (CD45RA+CD45RO−CD127int) (Figure 2); different median levels of expression of CD4 and CD127 appear to account for the generation of two clusters of naïve conventional T cells (Clusters 2 and 23), whereas expression of CD56 by Cluster 9 CD45RA+CD45RO−CD4+ T cells indicates that they may be unconventional NKT cells.

Clusters 5 and 15 define two different subpopulations of antigen-experienced CCR4+ CD4+ T cells (Figure 2). Based on the expression of CD25, the interleukin-2 receptor α chain (IL-2R) and lack of CD127, the interleukin-7 receptor α chain (IL-7R), Cluster 15 cells appear to be conventional regulatory T cells (Tregs) (24), and were found almost exclusively in the BIL fractions (Figure 5). Additional minor populations of CD45RO−CD25+CCR4+CD4+ T cells (Clusters 21, 22, 30, and 38) found predominantly in the blood may also be Tregs (Figure 2). Clusters 5 and 15 defined an activated effector memory population of CD4 T cells (CD45RO+HLA-DR+CD69+) (Figure 2) that was found in all of the BIL fractions (Figure 5). These cells also expressed the chemokine receptors CXCR3 and CCR5 thus may have trafficked to the epileptogenic brain area that was resected, possibly due to local inflammation (25).

Cluster 4 CD8+ T cells were primarily found in the PBMC fractions and appear to correspond to an activated unprimed subtype (CD45RA+CD127+) since they also expressed the
chemokine receptor CXCR3 (26). A CD45RA+ CD45RO− subpopulation (Cluster 14) made up most of the remaining CD8 T cells in the blood (Figures 2, 5; Table S4). Cells in Clusters 10 and 13 appear to be activated (CD69+ HLA-DR+) effector memory subtypes, and were found almost exclusively in the brain (Figures 2, 5). Based on the marker panel used in this study, the only difference between these two clusters was the expression of the resident memory marker CD103. Fewer Cluster 13 CD8+ resident memory T cells (TRM) were found in the brain compared with Cluster 10 T cells with one exception, Case ID 484, a RE patient. In agreement with previous work (27), the majority of the CD8+ T cells isolated from resected brain tissue from this patient were TRM cells. Likewise, the majority of γδ T cells isolated from a second RE case (Case ID 472) were TRM cells (Cluster 26, Figure 5) (27). Cluster 26 and Cluster 42 γδ T cells expressed the activation markers CD69 and HLA-DR and were almost exclusively found in the brain (Figures 2, 5). These two activated subsets comprised 88–98 percent of the γδ T cells in the RE BIL fractions, whereas a third subset, Cluster 11, a CCR5+ CXCR3+ effector memory population (CD45RA+ CD45ROint CD127+) contributed up 70 percent of the γδ T cells in the other cases (Table S4). The Cluster 11 subset also made up the vast majority of γδ T cells in the blood from all of the cases (Figure 5). We verified the existence of all of the major T cell populations defined by the ClusterX clustering algorithm by manually curating several of the original FCS files (Figures S1B–D).

The donut plots in Figure 6 summarize the proportion of CD69+ HLA-DR+ T cells found in each of the BIL fractions from the 10 surgery cases. At least 90 percent of the T cells isolated from the RE cases and 80 percent of the T cells from the HME case were activated. Even though T cells made up only a small fraction of the CD45+ cells isolated from the TSC and FCD cases, 40–66 percent of the T cells were also activated at the time of surgery.

The absence of CD8+ TRM cells in the BIL fraction from RE case ID 497 suggested that the disease may not have progressed as far in this patient compared with the other two RE cases in the study cohort (Cases IDs 472 and 484). A [18F]-deoxyglucose positron emission tomography (FDG-PET) brain scan of the patient made before the surgery showed hypometabolism extending over the entire affected hemisphere, with no definitive areas of atrophy. In the other two RE cases, areas of atrophy were clearly visible (Figure 7). Case ID 497 was the youngest of the three RE patients at the time of seizure onset and underwent surgery after the shortest time following onset of seizures (Table S1).

**DISCUSSION**

We have used CyTOF to gain a better understanding of the involvement of peripheral immune cells in intractable epilepsy in children. We implemented an unsupervised clustering method to resolve the resulting high dimensional data into the main subtypes of adaptive and innate lymphoid cells present in resected epileptogenic brain tissue. Our small cohort study, and other recent work (28) implicate cellular immunity not only in RE, but in intractable epilepsy in children where an infection or immune disorder is not suspected. With the caveat that we only analyzed a limited number of surgery cases, we found a clear difference in the relative number of innate vs. adaptive peripheral immune cells in fractions of CD45+ cells isolated from resected TSC and FCD brain tissue compared with involved RE brain tissue. The FCD and TSC BIL fractions were dominated by a single subset of NK cells (Cluster 8) and a population of myeloid cells (Cluster 1) that are likely to be macrophages, possibly classically activated pro-inflammatory M1 macrophages. Adding CD38 and CD163 antibodies to the staining panel will allow us to distinguish between M1 and M2 macrophages, respectively (29, 30). In an animal seizure model, infiltrating monocytes were shown to exacerbate neuronal damage (31), indicating that the abundant myeloid population that we found in the FCD and TSC BIL fractions may be pathologically relevant.

Most NK cells in the blood express a low level of CD56 (CD56dim) and are CD16+, thus can engage in antibody-dependent cell-mediated cytotoxicity by binding antibody-coated target cells via the low affinity Fcy receptor III (CD16) (32). Fewer circulating NK cells express a high level of CD56 (CD56bright); these cells generally lack CD16, but can produce pro- or anti-inflammatory cytokines (32). CD56bright NK cells are considered to be more immature than CD56dim NK cells in that they mostly do not express killer cell immunoglobulin-like receptors (KIRs) (33). Unlike CD56dim NK cells they express CD62L (L-selectin) and CD197 (CCR7), cell surface molecules that facilitate homing to secondary lymph nodes (32). CD56dim...
NK cells express KIRs and CD57 and are considered to be intrinsically more cytotoxic (32, 33). The most abundant NK cells that we found in the blood of all of the patients in our study cohort presumably correspond to CD56\textsuperscript{dim}CD16\textsuperscript{+} NK cells (Cluster 3). This subset also comprised the majority of NK cells present in the BIL fractions from the RE and HME patients (Figure 5). Adding CD62L, CD197, and CD57 to the marker panel will clarify the phenotype of Cluster 3 NK cells.

By comparison to the NK cells in the PBMC fractions, the majority of NK cells found in the FCD and TSC BIL fractions expressed a lower level of CD56\textsuperscript{dim} suggesting that they correspond to a CD56\textsuperscript{dim} subset (Cluster 8) (Figure 2, Figure S1A). Unlike canonical CD56\textsuperscript{dim} NK cells, Cluster 8 cells did not express...
CD16, however populations of CD56$^{\text{dim}}$ NK cells expressing little or no CD16 have been previously described (34). Lack of CD16 may be due to the fact that the Cluster 8 NK cells were highly activated; it has been reported that the Fcγ receptor III is proteolytically cleaved in degranulating CD56$^{\text{dim}}$ NK cells (35). In contrast to Cluster 3 NK cells, Cluster 8 NK cells also expressed HLA-DR (Figure 2, Figure S1A), which suggests that they may be adaptive NK cells (32, 33). A third population of NK cells (Cluster 33), only found in appreciable numbers in BILs from the HME case (Case ID 485) expressed CD69 along with CCR5, CXCR3, and CD103 suggesting that this cluster may correspond to an activated resident subset (32).

BIL fractions from the RE cases were predominantly CD8$^{\alpha\beta}$ and γδ effector memory and resident memory T cells with fewer effector memory CD4 T cells, confirming previous work (20, 27). We and others have shown that T cells found in RE brain are clonally focused (7–10), which strongly implicates an antigen-driven adaptive immune response in the etiology of RE, and is consonant with the idea that RE is an autoimmune disease (36). Finding T_{RM} CD8$^{\alpha\beta}$ and γδ T cells in affected RE brain tissue indicates that an earlier immune response had occurred that left...
a resident memory population in place. Compared with RE cases 472 and 484 however, no T_{RM} cells were present in the BILs isolated from RE case 497, suggesting that this case may represent an early stage of the disease. In support of this idea, brain atrophy, a feature of late phases of the disease (4), was not evident in an FDG-PET brain scan of RE case 497, but was in RE cases 472 and 484 (Figure 7).

In pathological specimens from FCD and TSC surgeries scattered T cells have been previously observed (16, 17), and in our study we found activated CD4, CD8, and γδ T cells in the BIL fractions from the FCD and TSC cases (Figure 6). Determining the clonal diversity of these T cells by sequencing Vβ chain third complementarity determining regions may indicate whether they are unspecific bystanders or presage an adaptive response against self-antigens. Binding of self-peptides would however depend on the MHC alleles carried by the individual (37–39). The proportion of activated T cells in the single HME case (Case ID 485), which exceeded the number of NK cells (Figure 4), may indicate that an autoimmune response had already occurred in this very young patient who suffered from severe seizures. Future recall assays in which T cells isolated from resected brain tissue are cocultured with autologous neurons and glia differentiated from patient-derived induced pluripotent stems cells will directly answer whether the T cells are autoreactive.

The immune cell profiles of peripheral blood from all of the cases comprised both naïve and antigen experienced T cells. γδ T cells that were CD127^+, CD45RO^+, CCR3^+, and CCR5^+ comprised the majority of γδ T cells in all of the PBMC samples, as well as in the FCD and TSC BILs (Cluster 11; Figures 2, 5, Figure S1D). They likely express Vβ2/Vγ9 TCR receptors (40) since Vβ2/Vγ9 γδ T cells make up a large fraction of circulating γδ T cells (41). Expression of CXCР3 and CCR5 would allow these γδ T cells to access sites of inflammation (26). CXCР3 expression by naïve CD45RA^+ CD8 T cells (Cluster 4; Figure 2, Figure S1C) indicates that they are activated (42), and that development into effector T cells may be enhanced (43, 44). Whether the presence of these T cell subsets in the blood is directly related to inflammation in the brain remains to be determined. In future work we plan to compare the immune cell profiles of blood collected at the time of surgery and after recovery from surgery. Removal of epileptogenic brain tissue, the potential source of inflammation may change the relative frequency of specific circulating T cell subsets. Such subsets could potentially be used as biomarkers to assess the extent brain inflammation in children presenting with intractable epilepsy.

The distribution of the two most abundant CCR4^+ CD4 T cell subsets (Clusters 5 and 15) differed between the blood and brain. Cluster 15 cells were almost exclusively found in BIL fractions, and appear to be activated effector memory-like Tregs (CD25^+ CD45RO^+CD69^+HLA-DR^+) (Figures 2, 5, Figure S1B). Tregs are also defined by expression of the transcription factor FOXP3 (45). Attention has focused on the innate response of brain resident microglia and astrocytes to seizures and on the pro-inflammatory molecules produced by these cells as drivers of epileptogenesis (46–48). In seizure models, chemokines and cytokines produced by activated microglia and astrocytes can cause blood brain barrier leakage, and can attract peripheral lymphoid and myeloid cells to the brain (31, 49–51). Our data suggest that this could be happening in children with chronic pharmacoresistant seizures. Intractable epilepsy might be viewed as a "sterile" infection in which T cells and other immune cells traffic to epileptogenic areas of the cerebral cortex in response to local seizure-driven inflammation. Activated T cells and NK cells for example could permanently alter brain circuitry by directly or indirectly damaging neurons (52–55). Adjunctive treatments that block the recruitment of pro-inflammatory peripheral lymphoid and myeloid cells to the brain (56–61) may therefore be therapeutically beneficial.

AUTHOR CONTRIBUTIONS

GO designed the study, analyzed the data, and wrote the paper. AG assisted with study design and performed the CyTOF. AM assisted with analysis of the data. JC and SR coordinated collection of surgical specimens and prepared BILs and PBMCs. RP assisted with study design and helped draft the paper. NS provided FDG-PET results. GM supported the project. AF provided support for the work, and provided surgical specimens and patient information.

ACKNOWLEDGMENTS

This work was supported by The RE Children’s Project and NIH/NCATS/UCLA CTSA UL1TR001881, and in part by NIH R01 NS083823 and U01 MH108898. GM was partly supported by the Davies/Crandall Endowed Chair for Epilepsy Research at UCLA.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.00121/full#supplementary-material
REFERENCES

1. Guerrini R. Epilepsy in children. Lancet (2006) 367:499–524. doi: 10.1016/S0140-6736(06)68182-8
2. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia (2006) 47:431–6. doi: 10.1111/j.1528-1167.2006.00440.x
3. Varadaraj S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. (2014) 13:195–205. doi: 10.1016/S1474-4422(13)70260-6
4. Bien CG, Urbach H, Deckert M, Schramm J, Wiestler OD, Lassmann H, et al. Diagnosis and staging of Rasmussen’s encephalitis by serial MRI and histopathology. Neurology (2002) 58:250–7. doi: 10.1212/WNL.58.2.250
5. Prayson RA, Frater JL. Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients. Am J Clin Pathol. (2002) 117:776–82. doi: 10.1309/AO8R-56OC-4V1-CSE2
6. Pardo CA, Vining EP, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropa thological studies in 45 hemispherectomies. Epilepsia (2004) 45:516–26. doi: 10.1111/j.1528-1167.2004.00310.x
7. Schwab N, Bien CG, Waschbich A, Becker A, Vince GH, Dormann K, et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain (2009) 132:1226–46. doi: 10.1093/brain/awp003
8. Schneider-Hohendorf T, Mohan H, Bien CG, Breuer J, Becker A, Gorlich D, et al. CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nat Commun. (2016) 7:11153. doi: 10.1038/ncomms11153
9. Dandekar S, Wijesuriya H, Geiger T, Hamm DM, Mathern GW, Owens GC. Shared HLA CLASS I and II alleles and clonally restricted public and private brain-infiltrating alphabeta T cells in a cohort of rasmussen encephalitis surgery patients. Front Immunol. (2016) 7:608. doi: 10.3389/fimmu.2016.00608
10. Al Nimer F, Jelcic I, Kempf C, Pieper T, Budka H, Sospedra M, et al. Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm. (2018) 5:e419. doi: 10.1212/NNIN.0000000000000419
11. Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun. (2017) 8:15816. doi: 10.1038/ncomms15816
12. Polchi A, Magini A, Meo DD, Tancini B, Emiliani C. mTOR Signaling and the Pathogenesis of Tuberous Sclerosis Complex. Biochim Biophys Acta Mol Basis Dis. (2019) 1852:2248–60. doi: 10.1016/j.bbadis.2018.09.017
13. Prayson RA, Frater JL. Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients. Am J Clin Pathol. (2002) 117:776–82. doi: 10.1309/AO8R-56OC-4V1-CSE2
14. Pardo CA, Vining EP, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropa thological studies in 45 hemispherectomies. Epilepsia (2004) 45:516–26. doi: 10.1111/j.1528-1167.2004.00310.x
15. Schwab N, Bien CG, Waschbich A, Becker A, Vince GH, Dormann K, et al. CD8+ T-cell clones dominate brain infil...
39. Gutierrez-Arcelus M, Rich SS, Raychaudhuri S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. *Nat Rev Genet.* (2016) 17:160–74. doi: 10.1038/nrg.2015.33

40. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: strong expression of CCR5 is a selective feature of V delta 2/V gamma 9 gamma delta T cells. *J Immunol.* (2002) 168:4920–9. doi: 10.4049/jimmunol.168.10.4920

41. Pang DJ, Neves JF, Sumaria N, Pennington DJ. Understanding the complexity of gammadelta T-cell subsets in mouse and human. *Immunology* (2012) 136:283–90. doi: 10.1111/j.1365-2567.2012.03582.x

42. Groom JR, Luster AD. CXCR3 ligand: redundant, collaborative and antagonistic functions. *Immunol Cell Biol.* (2011) 89:207–15. doi: 10.1038/ich.2010.158

43. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine receptor CXCR3 facilitates CDS(+) T cell differentiation into short-lived effector cells leading to memory degeneration. *J Exp Med.* (2011) 208:1605–20. doi: 10.1084/jem.20102101

44. Groom JR, Richmond J, Murooka TT, Sorensen EW, Sung JH, Bankert K, et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. *Immunity* (2012) 37:1091–103. doi: 10.1016/j.immuni.2012.08.016

45. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. *Nat Rev Neurol.* (2011) 7:31–40. doi: 10.1038/nrneurol.2010.178

46. Vezzani A, Auvin S, Ravizza T, Aronica E. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. *Jasper's Basic Mechanisms of the Epilepsies.* Bethesda, MD: Oxford University Press (2012).

47. Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. *Trends Neurosci.* (2013) 36:174–84. doi: 10.1016/j.tins.2012.11.008

48. Eyo UB, Murugan M, Wu LJ. Microglia-neuron communication in epilepsy. *Glia* (2017) 65:5–18. doi: 10.1002/glia.23006

49. Vezzani A, Ravizza T, Balosso S, Aronica E. Glia as a source of cytokines: implications for neuronal excitability and survival. *Epilepsia* (2008) 49 (Suppl. 2):24–32. doi: 10.1111/j.1528-1167.2008.01490.x

50. Fabene PF, Bramanti P, Constantin G. The emerging role for chemokines in epilepsy. *J Neuroimmunol.* (2010) 224:22–7. doi: 10.1016/j.neuroimmunol.2010.05.016

51. Fabene PF, Laudanna C, Constantin G. Leukocyte trafficking mechanisms in epilepsy. *Nat Immunol.* (2013) 55:100–4. doi: 10.1038/j.molimm.2012.12.009

52. Melzer N, Meuth SG, Wiendl H. CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. *Faseb J.* (2009) 23:3659–73. doi: 10.1096/fj.09-136200

53. Kreutzfeldt M, Berghalter A, Fernandez M, Bruck W, Steinbach K, Vorm M, et al. Neuroprotective intervention by interferon-gamma blockade prevents CD8+ T cell-mediated dendrite and synapse loss. *J Exp Med.* (2013) 210:2087–103. doi: 10.1084/jem.20122143

54. Ehling P, Melzer N, Budde T, Meuth SG. CD8(+) T cell-mediated neuronal dysfunction and degeneration in limbic encephalitis. *Front Neurol.* (2015) 6:163. doi: 10.3389/fneur.2015.00163

55. Di Liberto G, Pantelyushin S, Kreutzfeldt M, Page N, Musardo S, Coras R, et al. Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping. *Cell* (2018) 175:458–471 e19. doi: 10.1016/j.cell.2018.07.049

56. Sotgiu S, Murriighle MR, Constantin G. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report. *BMC Neurol.* (2010) 10:84. doi: 10.1186/1471-2377-10-84

57. Bittner S, Simon OL, Gobel K, Bien CG, Meuth SG, Wiendl H. Rasmussen encephalitis treated with natalizumab. *Neurology* (2013) 81:395–7. doi: 10.1212/WNL.0b013e31829c5ceb

58. Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS. CCR5 blockade for neuroinflammatory diseases—beyond control of HIV. *Nat Rev Neurol.* (2016) 12:95–105. doi: 10.1038/nrneurol.2015.248

59. Ayzenberg I, Hoepner R, Kleiter I. Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. *Ther Clin Risk Manag.* (2016) 12:261–72. doi: 10.2147/TCRM.S63558

60. Robert R, Juglair L, Lim EX, Ang C, Wang JH, Ebert G, et al. A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6. *PLoS ONE* (2017) 12:e0184278. doi: 10.1371/journal.pone.0184278

61. Liang F, Giordano C, Shang D, Li Q, Petrof BJ. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice. *PLoS ONE* (2018) 13:e0194421. doi: 10.1371/journal.pone.0194421

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.